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Abstract The ADA and the EASD recently published a
consensus statement for the medical management of hyper-
glycaemia in patients with type 2 diabetes. The authors
advocate initial treatment with metformin monotherapy and
lifestyle modification, followed by addition of basal insulin
or a sulfonylurea if glycaemic goals are not met (tier 1
recommendations). All other glucose-lowering therapies are
relegated to a secondary (tier 2) status and only recom-
mended for selected clinical settings. In our view, this
algorithm does not offer physicians and patients the
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ADOPT A Diabetes Outcome Progression Trial
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DPP-IV Dipeptidyl peptidase-4
GLP-1 Glucagon-like peptide-1
PROactive PROspective pioglitAzone Clinical Trial In
macroVascular Events
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comes and Regulation of glycaemia in
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Introduction
In August 2006, the ADA and the EASD published a joint
consensus algorithm for the medical management of
hyperglycaemia in type 2 diabetes [1]. Recently, an update
introduced a two-tier categorisation of ‘well validated’ and
‘less well validated’ therapies [2].
Tier 1 treatments are initial metformin monotherapy
and lifestyle modification, followed by addition of basal
insulin or a sulfonylurea if glycaemic goals are not met.
These interventions are considered to be: ‘the best
established and most effective and cost-effective thera-
peutic strategy for achieving the target glycaemic goals’.
Although the authors, Nathan et al., endorse metformin
plus insulin as a particularly effective combination, in
practice most physicians and patients faced with these
second-line options are likely to choose metformin plus a
sulfonylurea. Recommended tier 2 approaches for
second-line therapy comprise metformin plus either a
thiazolidinedione (pioglitazone, since the authors advise
against using rosiglitazone) or a glucagon-like peptide-1
(GLP-1) receptor agonist. The tier 2 treatments are
recommended for consideration in selected clinical settings
only.
The description of this publication as a consensus
statement of the ADA and EASD is misleading, as it has
not been formally endorsed by the two organisations.
Indeed, the ADA states that ‘consensus statements…are
not official ADA recommendations’, that they are ‘produced
under the auspices of the Association by invited experts’
and that they are ‘not subject to subsequent review or
approval’ [3]. In addition, the organisation has declared that
the consensus statement represents the authors’ views and
not the official opinion of the association [2]. Nevertheless,
the recommendations have been published under the auspices
of the two societies and are likely to have considerable
influence.
We are concerned that the authors of the consensus
statement have not consistently employed an evidence-
based approach; we also find many of their recommenda-
tions questionable. However, we acknowledge that some
data were not available at the time of publication of the
updated consensus statement. This paper critically assesses
the basis of the purported consensus and the resulting tiers
of treatment options.
Development process
Evidence-based guidelines have advanced medical practice
and supported optimal prescribing for many diseases, and
processes for their development are well established [4–6].
At the evidence collation stage, a systematic review of data
is performed using a search strategy designed to identify all
relevant data. The evidence base typically comprises a
complex mix of data of variable quality and relevance,
necessitating precise and explicit grading criteria [7]. A
systematic review may be followed by a meta-analysis, i.e.
a mathematical method of pooling the results of studies that
meet predefined criteria. In the absence of a suitable body
of evidence, expert/consensus opinion may be used.
However, such opinion becomes less influential as the
evidence grows. While gaps exist in the management of
type 2 diabetes, the evidence base is sufficiently large to
allow an evidence-based approach for many aspects.
Current ADA standards of care in diabetes therefore
classify expert consensus or clinical experience as the
lowest forms of evidence [8]. Once collated, a working
group discusses the data based on the evidence-based tables
and draws conclusions. Guidelines are then developed and
graded or weighted according to the strength of the
supporting evidence. The draft guidelines should be
subjected to peer (and sometimes public) review before
being finalised.
The recommendations of Nathan et al. [2] do not appear
to meet many of these standards. For example, the
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stated and there is no formal grading of evidence. The
authors cite the use of ‘clinical judgment, that is, our
collective knowledge and clinical experience’ as a
principal secondary source of evidence. The panel
comprised only seven physicians (five North American,
two European). It is therefore questionable whether some
recommendations can reflect the available evidence base,
as outlined below in terms of the key attributes of glucose-
lowering treatments.
Glucose-lowering effects
The selection of glycaemic targets and glucose-lowering
treatments should be individualised on the basis of patient-
specific factors (age, stage of diabetes, cardiovascular risk
factors, weight, risk associated with hypoglycaemia etc.)
and of effects on multiple pathophysiological aspects of
type 2 diabetes [9].
According to Nathan et al., glucose-lowering efficacy is
the principal factor by which drugs should be differenti-
ated. Their algorithm states that ‘The over-arching
principle in selecting a particular intervention will be its
ability to achieve and maintain glycaemic goals’ [2]. They
tabulate the reductions in HbA1c expected with different
classes used as monotherapy, but provide few supporting
references. Sulfonylureas and metformin are each said to
reduce HbA1c by 1.0% to 2.0%, although the baseline
levels, time-scale, patient populations, specific agent and
dose are not defined. Thiazolidinediones are said to reduce
HbA1c by 0.5% to 1.4%, suggesting lower glucose-
lowering efficacy, but this is not supported by evidence
from large, randomised head-to-head trials, which found
no significant differences vs sulfonylureas or metformin
[10, 11] and better long-term efficacy for thiazolidine-
diones [12]. A systematic evidence-based review also
supports the view that these agents produce similar
absolute reductions in HbA1c [13]. We agree with Nathan
et al. on the importance of maintaining long-term
glycaemic control. In this context, the relegation of
thiazolidinediones appears puzzling in light of evidence
from A Diabetes Outcome Progression Trial (ADOPT),
where rosiglitazone was significantly better than gliben-
clamide or metformin at maintaining glycaemic targets
over 4 years [12].
Meta-analysis of randomised controlled trials indicates
that GLP-1 receptor agonists (exenatide, liraglutide) also
reduce HbA1c by ∼1% and are non-inferior to active
comparators [14]. In a head-to-head study, liraglutide was
more effective than exenatide, presumably due to its
longer half-life [15]. On meta-analysis, the dipeptidyl
peptidase-4 (DPP-IV) inhibitors (sitagliptin, vildagliptin)
were slightly less effective than other oral glucose-
lowering agents [14, 16], but were non-inferior to
sulfonylureas over 52 weeks when added to metformin
[17, 18].
In type 2 diabetes, insulin is commonly initiated as add-
on therapy either as a basal dose of a long-acting analogue
(insulin glargine [A21Gly,B31Arg,B32Arg human insulin]
or insulin detemir [B29Lys(e-tetradecanoyl),desB30 hu-
man insulin]) or prandially using biphasic (premixed)
formulations, although the optimal approach and most
efficient use of the different long-acting, intermediate-
acting (e.g. NPH insulin), rapid-acting and biphasic
formulations remains controversial [19]. Nathan et al.
recommend the initiation of basal insulin, followed by
intensification, if required. However, a recent meta-
analysis suggests that greater reductions in HbA1c can be
achieved using biphasic or rapid-acting prandial formula-
tions rather than a basal approach [20]. Although the
recent 3-year results of the Treating To Target in Type 2
Diabetes study (4-T study) showed that basal (detemir-
based) or prandial (insulin aspart [B28Asp human insulin]-
based) insulin regimens provided better glycaemic control
when added to oral therapy vs adding to a biphasic
(aspart-based) regimen, total insulin dose was highest in
the basal group (88 U), prandial insulin use was higher in
the basal group (51 vs 28 U in the biphasic group) and
most patients eventually received more complex insulin
regimens irrespective of initial therapy [21]. Glargine
appears to offer no benefit in terms of glycaemic control
over NPH insulin, while detemir might be slightly less
effective than NPH [22].
Clearly, basal insulin has the advantage of greater
convenience. Moreover, detemir and glargine are associated
with less overall hypoglycaemia than multiple daily
injections of rapid-acting analogues and biphasic or NPH
insulin [22–27]. However, a systematic review suggests that
biphasic insulin is not associated with more nocturnal or
more severe hypoglycaemia than basal insulin analogues
[27]. In recent head-to-head studies, there was no difference
in glycaemic control or hypoglycaemia with glargine vs
detemir [28, 29].
Thus, basal insulin has potential advantages over
biphasic or prandial insulin regimens in terms of less
hypoglycaemia and less weight gain (see below).
However, accumulating evidence indicates that control
of postprandial hyperglycaemia is also important in
achieving HbA1c goals [30]. We suggest that, in some
patients, the glycaemic benefits of biphasic or prandial
insulin regimens outweigh the risk of hypoglycaemia and
these regimens should be positioned as alternatives for initial
insulin therapy according to an individualised approach.
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The effects of glucose-lowering treatments on cardiovascu-
lar outcomes are of central importance, as cardiovascular
disease is the major cause of death in patients with diabetes.
The consensus statement algorithm states: ‘there are
insufficient data to support one class (or combination)
of glucose-lowering agents over another with regard to
their effects on complications’ [2]. Certainly, few pro-
spective studies have assessed cardiovascular outcomes
during long-term treatment and the cardiovascular benefit-
risk relationship of some agents and combinations remains
controversial.
Metformin In the UK Prospective Diabetes Study (UKPDS),
‘intensive’ treatment starting with metformin in overweight
patients reduced the rate of all micro- and macrovascular
complications vs less intensive diet-based treatment alone.
This reduction was significantly greater than with sulfony-
lureas or insulin [32]. Metformin also conferred significant
reductions in diabetes-related death, all-cause death, myo-
cardial infarction and all macrovascular events combined vs
conventional treatment. A significant benefit vs sulfonylur-
eas or insulin was seen for all-cause death [33]. On 10-year
post-interventional follow-up, the significant reductions in
myocardial infarction, death and any diabetes-related
endpoint persisted [33]. Observational analyses have also
shown reduced rates of all-cause and cardiovascular
mortality with metformin vs sulfonylurea monotherapy
[34–36].
Therefore, there is some evidence for a significant
beneficial effect of initial metformin monotherapy on
cardiovascular outcomes. The UKPDS is often considered
to be the most compelling evidence for a macrovascular
benefit of any single glucose-lowering medication. How-
ever, the sample size was relatively small by current
standards. As Nathan et al. note, these findings require
confirmation [2].
Sulfonylureas There are no prospective data clearly
supporting an effect of sulfonylureas on macrovascular
outcomes. In 1970, the University Group Diabetes
Program (UGDP) Study reported a link between
tolbutamide and increased cardiovascular risk [37]. In
the UKPDS, ‘intensive’ therapy starting with sulfonylur-
eas or insulin reduced microvascular complications (most-
ly retinopathy) vs diet alone over 11 years, but did not
significantly reduce mortality or macrovascular complica-
tions (a 16% relative reduction in myocardial infarction
had borderline statistical significance) [38]. Individually,
neither chlorpropamide nor glibenclamide significantly
reduced these endpoints. After 10 years of post-
interventional, observational follow-up, significant reduc-
tions in myocardial infarction and death were observed in
patients initially randomised to sulfonylureas or insulin vs
conventional therapy, despite the convergence of glycae-
mic control and treatments [33]. However, this analysis
did not differentiate the relative effect of sulfonylureas or
insulin.
Recently, the Action in Diabetes and Vascular
Disease: Preterax and Diamicron-MR Controlled Evalu-
ation (ADVANCE) trial showed that intensive therapy
based on gliclazide significantly reduced the risk of a
combined macrovascular/microvascular endpoint (driven
mostly by reduced nephropathy) vs less intensive therapy,
but had no significant effect on macrovascular events alone
[39].
Observational analyses have shown higher rates of all-
cause and cardiovascular mortality with sulfonylurea vs
metformin monotherapy [34–37]. Sulfonylurea use was
also associated with in-hospital mortality among patients
undergoing coronary angioplasty [40].
Summary: glucose-lowering effects and a re-evaluation of the ADA/EASD algorithm 
￿  In the short term (<1 year), the glucose-lowering efficacy of monotherapy with metformin, 
sulfonylureas or thiazolidinediones (and probably glinides and incretin-based therapies) is similar 
and may not be a compelling factor on which to base treatment choice. As such, other 
advantages/disadvantages of these agents (e.g. hypoglycaemia risk, weight gain) should be afforded 
greater importance within the limits of approved indications (Table 1) [31] 
￿  More consideration should be given to long-term glucose control, including use of individual 
therapies or combinations with more sustained glucose-lowering effects 
￿  Metformin and sulfonylureas, recommended by Nathan et al. as Tier 1 agents [2], are inexpensive 
and improve short-term glycaemic control, but sulfonylureas in particular are associated with 
progressive treatment failure and may not be the most appropriate choice over the long term 
￿  The optimal approach to add-on (or indeed initial) insulin therapy remains unclear and should not be 
restricted solely to consideration of basal insulin therapy 
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oral agents recommended by Nathan et al. for routine
addition to metformin monotherapy [2]. No prospective
studies have demonstrated a benefit of this combination on
diabetes complications. Indeed, concerns about adverse
cardiovascular effects of biguanide/sulfonylurea combina-
tion therapy were raised by the UGDP study [41].
Subsequently, in the UKPDS, the addition of metformin
to sulfonylurea therapy was associated with an increased
risk of diabetes-related and all-cause death, although this
was not confirmed by an epidemiological analysis [32].
Observational studies have analysed cardiovascular out-
comes for metformin/sulfonylurea combination therapy
with conflicting results. Some found an increased risk of
all-cause and cardiovascular mortality, while others found
no association or reduced risk [42]. The difficulty of
excluding bias from observational studies is well known
and the potential for confounding should be considered.
However, a meta-analysis showed an increased risk of the
composite of cardiovascular hospitalisation or mortality
with sulfonylureas plus metformin vs either metformin
monotherapy, sulfonylurea monotherapy or diet [42].
Insulin Intensive insulin therapy has been shown to protect
against long-term macrovascular complications in type 1
diabetes [43] and against microvascular complications in
type 1 and type 2 diabetes [38, 44, 45]. However, there is
no clear evidence that insulin treatment as such reduces the
risk of macrovascular outcomes in type 2 diabetes [46].
In the UKPDS, insulin had no significant effect on any
macrovascular outcome [38] and its contribution to the
delayed benefit of intensive therapy at follow-up was not
investigated [33]. Observational studies have had
conflicting results, including increased and decreased risk
of cardiovascular events vs other therapies [47–50].
In the Diabetes and Insulin-Glucose infusion in Acute
Myocardial Infarction (DIGAMI) study in type 2 diabetes,
insulin infusion followed by insulin injections reduced
long-term mortality rates by 28% relative to conventional
routine glucose-lowering therapy [51]. This contrasted with
DIGAMI-2, which reported no difference in total mortality
rates and a trend towards more non-fatal recurrent myocar-
dial infarction and stroke in patients receiving acute and
chronic insulin therapy vs routine therapy (with or without
acute insulin) [52]. A post-hoc analysis from DIGAMI-2
found that the risk of non-fatal myocardial infarction and
stroke increased significantly in patients on insulin at
discharge (vs no insulin), was unchanged with sulfonylur-
eas and decreased with metformin [53]. The Hyperglycemia
and its Effect after Acute Myocardial Infarction on Cardio-
vascular Outcomes in Patients with Type 2 Diabetes Mellitus
(HEART2D) Study failed to show any benefit of prandial vs
basal insulin on cardiovascular outcomes following acute
myocardial infarction [54].
Thiazolidinediones The effect of thiazolidinediones on
cardiovascular outcomes has received considerable atten-
tion in recent years and these agents are now perhaps the
best studied in this respect.
Data from several sources suggest that cardiovascular
risk is reduced with pioglitazone [55–58]. In the PRO-
spective pioglitAzone Clinical Trial In macroVascular
Events (PROactive) trial, participants with type 2 diabetes
and macrovascular disease were randomised to pioglitazone
vs placebo, alongside guideline-driven therapy [55, 56].
The primary endpoint, a composite of coronary, cerebro-
vascular and peripheral macrovascular events, showed a
trend towards benefit from pioglitazone. The main second-
ary endpoint (death, myocardial infarction or stroke)
showed a significant effect favouring pioglitazone. In
subgroup analyses, pioglitazone significantly reduced the
risk of recurrent myocardial infarction and recurrent stroke
[56]. In subsequent meta-analyses, pioglitazone was asso-
ciated with reduced rates of all-cause death [57] and of the
composite of death, myocardial infarction and stroke [58].
In a UK retrospective cohort study, pioglitazone was
associated with a lower risk of all-cause mortality than
metformin and a favourable risk profile vs rosiglitazone
[36].
Nathan et al. [2] note well publicised meta-analysis data
suggesting an increased risk of myocardial infarction with
rosiglitazone [59, 60] and advise against its use [2].
However, additional meta-analyses have not all reached
t h es a m ec o n c l u s i o n[ 61]. Recently, the Rosiglitazone
Evaluated for Cardiac Outcomes and Regulation of Gly-
caemia in Diabetes (RECORD) study, which looked at
rosiglitazone added to metformin or a sulfonylurea vs
metformin/sulfonylurea combination, was inconclusive on
possible adverse effects on myocardial infarction, but
suggested no impact on overall cardiovascular morbidity
or mortality [62]. Large observational analyses have
contributed additional real-world evidence with conflicting
results [63, 64]. Thus, the cardiovascular benefit–risk
profile of rosiglitazone remains controversial.
Incretin-based therapies Glucagon-like peptide-1 infusion
has been shown to confer beneficial cardiovascular effects
(using ‘soft’ surrogate endpoints) in patients with or
without diabetes [65]. Moreover, animal studies with
GLP-1 agonists suggest the potential to reduce infarct size
and improve survival after myocardial infarction [65–67].
However, no completed clinical studies have yet examined
the effect of GLP-1 agonists or DPP-IV inhibitors on
primary ‘hard’ cardiovascular endpoints.
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Nathan et al. acknowledge that drug effects on non-
glycaemic cardiovascular risk factors may be important
[2]. However, little explicit consideration of the evidence
supporting the relative benefit of different agents is
provided, and these properties do not appear to have
influenced the recommendations. We argue that effects on
the pathophysiological abnormalities in type 2 diabetes and
in cardiovascular disease warrant greater consideration.
Beta cell protection The importance of progressive beta
cell failure in the pathophysiology of type 2 diabetes is well
recognised [9, 68]. Sulfonylureas, in particular, are associ-
ated with rapid beta cell decline and treatment failure [9,
12, 32, 38]. Although metformin is associated with beta cell
decline, studies suggest that it is not as marked as with
sulfonylureas [9, 12, 32].
Accumulating data suggest that thiazolidinediones, GLP-1
agonists and DPP-IV inhibitors may help to maintain beta
cell mass and function [9, 68]. For thiazolidinediones, this is
consistent with: (1) the maintenance of durable glucose
control seen in randomised controlled trials over several
years [9, 12]; (2) the delay of treatment failure with
rosiglitazone vs either metformin or glibenclamide in
ADOPT [12]; and (3) the delayed progression to diabetes
seen in prediabetic patients [69, 70].
Analyses of intensive insulin therapy vs oral agents
(metformin, gliclazide) in patients with new-onset type 2
diabetes found that recovery and maintenance of beta cell
function (HOMA-B) was more favourably affected with
insulin [71, 72].
In clinical studies with adjunctive exenatide, short-term
reductions in HbA1c have been maintained for over 3 years
during open-label extension [9, 15, 73]. Beta cell function
was significantly improved with exenatide compared with
insulin glargine over 1 year, but returned to pre-treatment
values 4 weeks after treatment cessation [74]. Evidence from
short-term clinical studies suggests that liraglutide and DPP-
IV inhibitors may also benefit beta cell function [9, 15].
Anti-atherogenic effects Atherogenic risk factors associated
with type 2 diabetes include a characteristic dyslipidaemia
profile, subclinical inflammation, hypertension and obesity
[75]. Different glucose-lowering agents have very distinct
patterns of effects on these factors, which may confer
antiatherogenic benefits (Table 1). Metformin appears to
improve the lipid profile, with decreases in triacylglycerol
and LDL-cholesterol levels and (in some studies) increases
in HDL-cholesterol [76]. Thiazolidinediones improve dia-
betic dyslipidaemia, with benefits for pioglitazone over
sulfonylureas, metformin and rosiglitazone [77, 78]. A
systematic review found that, while thiazolidinediones, sulfo-
nylureas and metformin were equally effective at improving
glycaemiccontrol,onlymetforminimprovedLDL-cholesterol,
only thiazolidinediones improved HDL-cholesterol, and both
metformin and thiazolidinediones improved blood pressure
[13]. Studies using surrogate clinical measures of atheroscle-
rosis showed that pioglitazone significantly slowed progres-
sion of carotid intima–media thickness and prevented
progression of coronary atherosclerosis vs glimepiride [79,
80]. Insulin may exert anti-inflammatory actions that could be
anti-atherogenic/cardioprotective, although this remains con-
troversial [81]. Insulin may also lower LDL-cholesterol and
triacylglycerol levels [82, 83].
Exenatide and liraglutide may also exert benefits beyond
glucose control, such as reduced blood pressure and weight
loss [15]. While exenatide had no short-term effect on
plasma lipids, significant benefits were observed during
3 years of open-label treatment in responders [73]. DPP-IV
inhibitors may affect postprandial lipaemia [84].
Therapeutic effects of glucose-lowering agents on inflam-
matorymediators,haemostasis markersandother factors such
as the anti-inflammatory mediator adiponectin (which is
increased by thiazolidinediones) may also have clinical
relevance [85, 86].
Effects on body weight Management of type 2 diabetes should
not neglect effects on body weight. Weight gain is an important
disadvantage of sulfonylurea and insulin therapy. In the
UKPDS, absolute average weight gain was 6.5 kg in the insulin
 
 
 
 
Summary: cardiovascular benefit−risk relations and a re-evaluation of the ADA/EASD algorithm 
￿  Due to the high risk of macrovascular events in type 2 diabetes and absence of any well-established 
macrovascular benefit for glucose-lowering as such, more consideration should be given to the 
macrovascular benefit−risk profiles of individual glucose-lowering therapies. At present, there is 
good evidence of benefit for metformin (as initial therapy) in primary prevention and for 
pioglitazone (as part of guideline-driven therapy) in secondary prevention 
￿  Special emphasis on metformin/sulfonylurea as the combination of choice is questionable in the 
absence of any outcomes data and considering evidence of a potential adverse impact on outcomes 
￿  While caution is appropriate, exclusion of rosiglitazone from the algorithm (based on a perceived 
increased risk of myocardial infarction from low-grade evidence) may be unfounded considering the 
lack of any adverse impact on overall cardiovascular morbidity and mortality rates in RECORD 
[62]  
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Intervention Main advantages Main disadvantages
Metformin ￿Reduces macrovascular risk ￿Gastrointestinal side effects
￿Weight loss ￿Potential cardiovascular safety issues in
combination with sulfonylureas ￿Low risk of hypoglycaemia
￿Lactic acidosis (rare in patients without
contraindications)
￿Improved multiple cardiovascular risk factors/markers
(lipids, CRP, PAI-1, thrombocyte hyperactivity)
￿Drug costs
￿FDCs available (with sulfonylureas, thiazolidinediones,
DPP-IV inhibitors)
Sulfonylureas ￿Reduces microvascular risk (glibenclamide) ￿Rapid secondary failure (vs metformin or
thiazolidinediones) ￿Reduces nephropathy (gliclazide)
￿Weight gain (varies between different agents) ￿Drug costs
￿Moderate risk of hypoglycaemia
(varies between different agents)
￿FDCs available (with metformin, thiazolidinediones)
￿Potential cardiovascular safety issues, especially
in combination with metformin
Thiazolidinediones ￿More sustained glucose control
(vs metformin or sulfonylureas)
￿Weight gain
￿Reduced macrovascular risk (pioglitazone only)
￿Peripheral oedema
￿Low risk of hypoglycaemia
￿Uncertain macrovascular risk profile with
rosiglitazone
￿Reduced atherosclerosis progression
(coronary IVUS [pioglitazone only], CIMT)
￿Increased incidence of CHF (but no increased
macrovascular/ mortality consequences)
￿Improved multiple cardiovascular risk factors/markers
(lipids, blood pressure, CRP, adiponectin,
PAI-1, MMP-9)
￿Increased risk of distal fractures in women
￿Reduced microalbuminuria
￿Drug costs
￿FDCs available (with metformin, glimepiride)
Glinides ￿Reduces postprandial blood glucose ￿No outcomes data
￿Hypoglycaemia (possibly similar risk to sulfonylureas)
￿Weight gain
￿Long-term efficacy/safety data lacking
(especially in combination with other oral agents)
￿Drug costs
α-Glucosidase inhibitors ￿Weight neutral ￿No robust cardiovascular outcomes data
￿Low risk of hypoglycaemia ￿Gastrointestinal side effects (leading to poor adherence)
￿Serious side effects extremely rare ￿Glucose-lowering efficacy only modest
DPP-IV inhibitors ￿Low risk of hypoglycaemia
(except in combination with a sulfonylurea)
￿No outcomes data
￿Weight-neutral
￿Limited long-term clinical experience at present
￿FDCs available (with metformin)
￿Possible link to pancreatitis
￿Drug costs
Insulin ￿Glucose-lowering efficacy
(potentially limitless with uptitration)
￿Most effective insulin strategy remains undetermined
￿Reduces microvascular risk
￿Moderate to high risk of hypoglycaemia
￿Weight gain
￿Frequent blood glucose monitoring
￿May involve frequent injections
￿Drug costs (esp. analogues)
GLP-1 receptor agonists ￿Low risk of hypoglycaemia
(except in combination with a sulfonylurea)
￿No outcomes data
￿Weight loss
￿Gastrointestinal side effects
￿Lowers blood pressure ￿Limited long-term clinical experience at present
￿Potential beta cell protective effect ￿Antibody formation (exenatide only)
￿Possible interaction with other drugs due to
delayed gastric emptying
￿Possible link to pancreatitis
￿Drug costs
Adapted and modified from the evidence-based guideline of the German Diabetes Association [31]
CIMT, carotid intima–media thickness; CRP, C-reactive protein; FDC, fixed-dose combination; IVUS, intravascular ultrasound; MMP-9, matrix
metalloproteinase-9; PAI-1, plasminogen activator inhibitor-1
1264 Diabetologia (2010) 53:1258–1269group over 10 years. Relative to dietary therapy, it was 4.0, 2.6
and 1.7 kg with insulin, chlorpropamide and glibenclamide,
respectively [38]. Although all insulins increase body weight,
prandial (and probably biphasic) regimens generally produce
more weight gain than basal regimens [20]. Basal detemir, in
particular, consistently shows less weight gain than other
formulations, including NPH and glargine [22, 28, 29].
Pioglitazone and rosiglitazone also produce weight gain.
In PROactive, the increase was 3.6 kg with pioglitazone
over 3 years and in ADOPT it was 4.8 kg with rosiglitazone
over 5 years [12, 55]. Despite this, thiazolidinediones
ameliorate insulin resistance and the weight gain appears
to correlate with improvements in HbA1c [87, 88].
Exenatide, liraglutide and metformin reduce body weight
in monotherapy and limit weight gain in combination with
sulfonylureas, thiazolidinediones and/or insulin [15, 89].
DPP-IV inhibitors are essentially weight neutral [16].
Consideration of adverse effects
Fluid retention and congestive heart failure The potential
for fluid retention and exacerbation of congestive heart failure
(CHF) with thiazolidinediones is well recognised [90].
However, this does not appear to increase cardiovascular
mortality rates and appropriate treatment of oedema will
prevent CHF [90]. In PROactive, pioglitazone recipients
experienced more serious heart failure events than partic-
ipants on placebo, but without increased heart failure
mortality rates [90]. Among patients with serious heart
failure events, pioglitazone significantly lowered the risk of
the main secondary endpoint vs placebo, with a trend
towards lower risk for the primary endpoint and all-cause
mortality [90]. A meta-analysis of controlled studies con-
cluded that metformin is the only glucose-lowering agent not
associated with measurable harm in patients with diabetes
and heart failure, although randomised trials are lacking and
warnings concerning lactic acidosis remain [91].
Bone fracture risk Pioglitazone and rosiglitazone are associ-
ated with double the risk offractures vs other oral agents [92].
Rates are two to three fractures per 100 patient-years, with
most occurring in the distal long bones and related to trauma.
This risk should be a particular consideration in postmeno-
pausal women.
Gastrointestinal side effects One of the few limitations of
metformin is intolerance to its gastrointestinal side effects
in a moderate proportion of patients [31]. This is also the
main adverse event associated with exenatide [31].
Acute pancreatitis Post-marketing cases of acute pancreatitis
(including haemorrhagic/necrotising pancreatitis) have been
reported with incretin-based therapies, including exenatide
and sitagliptin [93, 94]. In clinical trials, however, the
incidence was 1.79/1,000 person-years for exenatide (seven
cases), 2.72 with placebo and 1.35 for comparators [95].
Recently, data from a large US health insurance database
suggested annual acute pancreatitis rates of 0.13% among
exenatide users and 0.12% among sitagliptin users [96]. This
was comparable with the risk from metformin and gliben-
clamide, making evidence of an association between acute
pancreatitis and incretin-based therapies weak at best [96].
Cancer Malignancyisanemergingpotentialsafetyissuewith
some glucose-lowering therapies. Observational studies sug-
gest that insulin or insulin secretagogues may be associated
with increased risk of pancreatic cancer, whereas metformin
may be associated with reduced cancer risk [97–99]. In a
recent retrospective cohort study in general practice, patients
oninsulinorinsulinsecretagoguesweremorelikelytodevelop
solid cancers vs those on metformin, most of this excess risk
being abolished by combination with metformin [99].
Hypoglycaemia Iatrogenic hypoglycaemia represents a barrier
to intensive glucose control, and is a particular issue with insulin
and (to some extent) sulfonylureas.Most guidelines recommend
HbA1c targets below 7.0% or 6.5% [2, 8, 31, 100], but without
reference to specific antidiabetic treatments, diabetes duration
or pre-existing cardiovascular disease. In the Action to Control
Cardiovascular Risk in Diabetes (ACCORD) study, intensive
control was associated with increased all-cause and cardiovas-
cular mortality vs conventional therapy [100]. After 3.5 years,
HbA1c was 6.4% with intensive treatment and 7.5% with
conventional treatment, and severe hypoglycaemic event rates
were 10.5% and 3.5%, respectively. Although the cause of the
increased mortality remains unclear, hypoglycaemia represents
the most plausible explanation. Recently, alarming results from
the statistically powerful UK General Practice Research
Database have been published [101]. Among 48,000 patients
with type 2 diabetes, the decile with the lowest HbA1c (median
6.4%) had a significantly higher mortality rate (HR 1.52, 95%
CI 1.32–1.76) vs the lowest-risk reference decile (median
HbA1c 7.5%), and the rate was higher than all other deciles
apart from the highest HbA1c (median 10.5%). Major
cardiovascular events were also more frequent in this low
HbA1c group than any other decile. Within the lowest decile,
insulin-treated patients had a greater mortality risk vs the
reference decile (HR 1.79, 95% CI 1.45–2.22) than those not
treated with insulin (HR 1.30, 95% CI 1.07–1.58), adding
support to the hypothesis that premature death might relate to
hypoglycaemia. Future controlled intervention studies are
needed to clarify whether intensification of glucose control
with insulin therapy alone further heightens mortality risk.
Accordingly, diabetes guidelines might need revision to
define a minimum HbA1c value, especially for patients with
long-standing diabetes or established cardiovascular disease.
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The algorithm published by Nathan et al. [2] under the
auspices of the ADA and EASD has provoked debate on the
optimal management of hyperglycaemia in type 2 diabetes
[9, 102]. This paper is not designed to propose a specific
treatment algorithm, but rather to point out important
deficiencies in the algorithm of Nathan et al. and to argue
for a re-evaluation of its recommendations. We believe that
inconsistencies in the application of accepted evidence-based
procedures have resulted in a skewed ranking of agents. In
our opinion, the recommended two-tier approach is not
evidence based and does not offer the best quality of
treatment on the basis of our understanding of the multifac-
torial pathophysiology of type 2 diabetes or the need for
individualised therapy. Methodologically, the ADA–EASD
algorithm seems to be based more on an outdated expert
opinion model than on the evidence-based approach that
represents the current standard for guideline development.
In our opinion, these recommendations do not take full
account of the evidence on the appropriate priorities for
treatment (in particular, the potential impact on clinically
important endpoints such as macrovascular events) or on
the benefits of all available classes of glucose-lowering
agents. In favouring initial use of metformin monotherapy
followed by sulfonylurea, an approach known to fail, this
algorithm does not offer physicians and patients the
appropriate selection of options to individualise and
optimise care with a view to sustained control of blood
glucose and reduction of diabetes complications.
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